Aethlon Medical (NASDAQ:AEMD – Get Free Report) is anticipated to announce its Q4 2025 earnings results before the market opens on Thursday, June 26th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.
Aethlon Medical Stock Down 11.4%
Shares of NASDAQ AEMD opened at $1.40 on Tuesday. The firm has a fifty day simple moving average of $2.76 and a 200 day simple moving average of $3.80. Aethlon Medical has a twelve month low of $1.40 and a twelve month high of $8.44. The company has a market capitalization of $2.81 million, a PE ratio of -0.11 and a beta of 1.89.
Wall Street Analyst Weigh In
AEMD has been the subject of a number of research analyst reports. Wall Street Zen initiated coverage on Aethlon Medical in a report on Thursday, May 15th. They issued a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $56.00 price objective on shares of Aethlon Medical in a research note on Monday, March 10th.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- Health Care Stocks Explained: Why You Might Want to Invest
- Microsoft Stock Holds Steady as AI Drives Workforce Shift
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- D-Wave Goes International With South Korea Partnership
- Comparing and Trading High PE Ratio Stocks
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.